Evidence map›Paper›PMID 39679258›Full record

ArticleFrontiers in aging neuroscience2024

Advanced AI techniques for classifying Alzheimer's disease and mild cognitive impairment.

Sophie Tascedda, Pierfrancesco Sarti, Veronica Rivi, Claudia Savia Guerrera, Giuseppe Alessio Platania, Mario Santagati, Filippo Caraci, Johanna M C Blom

Abstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sophie Tascedda *Plateforme de Bioinformatique, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
Pierfrancesco Sarti *Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Veronica RiviDepartment of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Claudia Savia GuerreraDepartment of Educational Sciences, University of Catania, Catania, Italy.
Giuseppe Alessio PlataniaDepartment of Educational Sciences, University of Catania, Catania, Italy.
Mario SantagatiASP3 Catania, Department of Mental Health, Alzheimer Psychogeriatric Centre, Catania, Italy.
Filippo CaraciDepartment of Drug and Health Sciences, University of Catania, Catania, Italy.
Johanna M C BlomService de Chimie Clinique CHUV, Lausanne, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Alzheimer's disease and mild cognitive impairment are often difficult to differentiate due to their progressive nature and overlapping symptoms. The lack of reliable biomarkers further complicates early diagnosis. As the global population ages, the incidence of cognitive disorders increases, making the need for accurate diagnosis critical. Timely and precise diagnosis is essential for the effective treatment and intervention of these conditions. However, existing diagnostic methods frequently lead to a significant rate of misdiagnosis. This issue underscores the necessity for improved diagnostic techniques to better identify cognitive disorders in the aging population. Methods: We used Graph Neural Networks, Multi-Layer Perceptrons, and Graph Attention Networks. GNNs map patient data into a graph structure, with nodes representing patients and edges shared clinical features, capturing key relationships. MLPs and GATs are used to analyse discrete data points for tasks such as classification and regression. Each model was evaluated on accuracy, precision, and recall. Results: The AI models provide an objective basis for comparing patient data with reference populations. This approach enhances the ability to accurately distinguish between AD and MCI, offering more precise risk stratification and aiding in the development of personalized treatment strategies. Conclusion: The incorporation of AI methodologies such as GNNs and MLPs into clinical settings holds promise for enhancing the diagnosis and management of Alzheimer's disease and mild cognitive impairment. By deploying these advanced computational techniques, clinicians could see a reduction in diagnostic errors, facilitating earlier, more precise interventions, and likely to lead to significantly improved outcomes for patients.

Indexed as

artificial intelligencedeep learningdementiagraph convolutional networksmachine learningneural networks

Identifiers

PMID39679258
PMCPMC11638155

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.